| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_545917c7384f2a993d6047c35ea366a3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70589
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-723
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4742 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
| filingDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b152395c8edb48c40cae784ca7918f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b1a70fa31d257bdd6aeead4bbed6ffa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e145e65e4686d85870d74b453309274b |
| publicationDate |
2018-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018064678-A1 |
| titleOfInvention |
Use of cabazitaxel in the treatment of prostate cancer |
| abstract |
The present invention relates to cabazitaxel for use in a method for treating an AR-V7-positive patient suffering from prostate cancer comprising determining the AR-V7-status in said patient and administering cabazitaxel. The invention also relates to a method of identifying patients with prostate cancer, eligible for treatment with cabazitaxel comprising testing a biological sample from the patient for the presence of AR-V7 circulating tumor cells, wherein the patient is eligible for treatment with said cabazitaxel if circulating tumor cells in said sample test positive for AR-V7. The invention further relates to a kit of parts for determining the AR-V7-status in isolated tumor cells of a patient with prostate cancer. |
| priorityDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |